SuperworthStryker SYK
- Market cap
- $117.8B
- PE
- 31.8×
- 10y median 41.2×
- Forward PE
- 19.3×
- 10y median 25.9×
- Price to sales
- 4.6×
- EV/EBIT
- 23.4×
- Revenue, 12 months
- $25.8B
- +8% on a year ago
- Net margin
- 14.4%
- Free cash flow yield
- 4.0%
Stryker trades at 31.8× trailing earnings, cheaper than 80% of the last ten years. Revenue was $25.8B over the last twelve months, up 8% on a year earlier with a 14% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.9B+10% | $5.8B+12% | $5.2B+10% | $5.4B+9% | $5.5B+12% | $6.4B+11% | $5.9B+12% | $6B+11% | $6.1B+10% | $7.2B+11% | $6B+3% | $6.6B+9% | |
| Cost of revenue | $1.8B+3% | $2.1B+7% | $1.9B+8% | $2B+11% | $2B+13% | $2.3B+7% | $2.1B+11% | $2.2B+9% | $2.2B+12% | $2.5B+12% | $2.2B+4% | $2.1B−4% |
| Gross profit | $3.2B+14% | $3.7B+14% | $3.3B+11% | $3.4B+7% | $3.5B+11% | $4.2B+13% | $3.7B+12% | $3.8B+12% | $3.9B+10% | $4.6B+11% | $3.8B+2% | $4.5B+17% |
| R&D | $353M−3% | $350M+7% | $368M+9% | $363M+5% | $377M+7% | $358M+2% | $405M+10% | $407M+12% | $410M+9% | $401M+12% | $413M+2% | $434M+7% |
| SG&A | $1.7B+18% | $1.9B+9% | $1.8B+3% | $1.8B+7% | $1.9B+11% | $2.1B+11% | $2.3B+25% | $2.1B+14% | $2B+8% | $2.2B+5% | $2.3B−1% | $2.2B+7% |
| $931M+15% | $1.3B+54% | $972M+32% | $1.1B+9% | $1.1B+17% | $581M−54% | $837M−14% | $1.1B+6% | $1.1B+5% | $1.8B+211% | $936M+12% | $1.7B+49% | |
| Interest expense | n/a | n/a | n/a | $96M | $98M | $117M | $137M | $159M+66% | $157M+60% | $154M+32% | $148M+8% | $141M−11% |
| Pre-tax income | $869M+7% | $1.2B+61% | $923M+36% | $998M+11% | $1B+20% | $528M−57% | $764M−17% | $1B+2% | $1B−1% | $1.7B+223% | $850M+11% | $1.6B+54% |
| $177M | $83M−58% | $135M+55% | $173M+8% | $209M+18% | −$18M | $110M−19% | $132M−24% | $170M−19% | $856M | $105M−5% | $288M+118% | |
| Net income | $692M−15% | $1.1B+103% | $788M+33% | $825M+12% | $834M+21% | $546M−52% | $654M−17% | $884M+7% | $859M+3% | $849M+56% | $745M+14% | $1.3B+44% |
| $1.80−16% | $2.98+103% | $2.05+33% | $2.14+11% | $2.16+20% | $1.41−53% | $1.69−18% | $2.29+7% | $2.22+3% | $2.20+56% | $1.93+14% | $3.30+44% | |
| 384M+1% | 383.7M+0% | 385.1M+1% | 385.4M+0% | 385.6M+0% | 386.2M+1% | 386.4M+0% | 386.4M+0% | 386.7M+0% | 386.5M+0% | 386.5M+0% | 386M−0% |
EPS, diluted: Q4 FY08 and Q4 FY09: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'.
Diluted shares: 15 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $6.6B | $6.5B to $6.6B | $3.55 | $3.46 to $3.76 | 17 |
| Q4 FY26 | $8B | $7.9B to $8B | $5.12 | $5.02 to $5.20 | 16 |
| Q1 FY27 | $6.6B | $6.6B to $6.7B | $3.29 | $3.24 to $3.33 | 8 |
| Q2 FY27 | $7.1B | $7B to $7.2B | $3.97 | $3.92 to $4.03 | 7 |
| Q3 FY27 | $7.2B | $7.1B to $7.2B | $4.00 | $3.94 to $4.06 | 7 |
| Q4 FY27 | $8.6B | $8.5B to $8.7B | $5.46 | $5.38 to $5.53 | 12 |
| Q1 FY28 | $7.1B | $7B to $7.1B | $3.72 | $3.67 to $3.77 | 9 |
| Q2 FY28 | $7.7B | $7.6B to $7.7B | $4.38 | $4.32 to $4.44 | 8 |
Peers
Companies in Medical - Devices nearest Stryker's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SYKStryker | $117.8B | 31.8× | 41.2× | 19.3× | 4.6× | +8% | 14.4% |
| MDTMedtronic | $122B | 23.4× | 28.2× | 15.9× | 3.3× | +10% | 13.9% |
| ABTAbbott Laboratories | $179.4B | 38.7× | 36.7× | 17.7× | n/m | n/m | n/m |
| BSXBoston Scientific | $66.2B | 18.5× | 67.0× | 14.1× | 3.2× | +14% | 17.5% |
| EWEdwards Lifesciences | $51.3B | 51.2× | 40.3× | 28.3× | 7.9× | +15% | 15.4% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| Peer median | $51.3B | 24.0× | 36.7× | 16.8× | 3.2× | +12% | 14.7% |
Investors who own it
Investors we follow who held Stryker at the end of Jun 30, 2026, from their 13F filings.
- Terry SmithFundsmith6.7% of portfoliotrimmed
More on Stryker
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 34Healthcare stocks with the lowest PEG ratio
- #6of 17Medical device stocks with the highest profit margins
- #6of 12Medical device stocks with the fastest earnings growth
- #7of 13Medical device stocks with the highest free cash flow yield
- #8of 13Medical device stocks with the lowest EV/EBIT
- #10of 13Medical device stocks with the lowest PE ratio
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .